Amy Bachrodt, SVP, Finance at Maze Therapeutics, Inc. (MAZE), sold 9,800 shares at $44.15 ($452K) on 2026-02-02, disclosed to the SEC on 2026-02-04.
Open-market sale of $452k MAZE by SVP, Finance. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $44.15 | 200 | $9K | 2.0% |
| 2 | $46.03 | 4,064 | $187K | 41.4% |
| 3 | $46.03 | 4,064 | $187K | 41.4% |
| 4 | $46.63 | 736 | $34K | 7.6% |
| 5 | $46.63 | 736 | $34K | 7.6% |
| Total | $46.08 avg | 9,800 |
| $452K |
| 100% |
| Filing → |
| MAZE | SELL | 2026-01-26 | $455K | — | Filing → |
| MAZE | SELL | 2026-01-06 | $392K | — | Filing → |
| MAZE | SELL | 2025-12-31 | $606K | — | Filing → |